NASDAQ:ATYR aTyr Pharma (ATYR) Stock Price, News & Analysis $0.43 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$0.43 +0.00 (+0.05%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About aTyr Pharma Stock (NASDAQ:ATYR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get aTyr Pharma alerts:Sign Up Key Stats Today's Range$0.42▼$0.4550-Day Range$0.43▼$0.6552-Week Range$0.40▼$6.50Volume1.41 million shsAverage Volume638,822 shsMarket Capitalization$42.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors. The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas. Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.AI Generated. May Contain Errors. Read More aTyr Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreATYR MarketRank™: aTyr Pharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 865th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingHold Consensus RatingaTyr Pharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 1 buy rating, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageaTyr Pharma has only been the subject of 1 research reports in the past 90 days.Read more about aTyr Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for aTyr Pharma are expected to decrease in the coming year, from ($0.44) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of aTyr Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of aTyr Pharma is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioaTyr Pharma has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about aTyr Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.04% of the float of aTyr Pharma has been sold short.Short Interest Ratio / Days to CoveraTyr Pharma has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.Change versus previous monthShort interest in aTyr Pharma has recently decreased by 1.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldaTyr Pharma does not currently pay a dividend.Dividend GrowthaTyr Pharma does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.94 News SentimentaTyr Pharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for aTyr Pharma this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for ATYR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows5 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, aTyr Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.75% of the stock of aTyr Pharma is held by insiders.Percentage Held by Institutions61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about aTyr Pharma's insider trading history. Receive ATYR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATYR Stock News HeadlinesSarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsightSeptember 8, 2026 | finance.yahoo.comATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung DiseaseSeptember 2, 2026 | rttnews.comA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn.September 14 at 1:00 AM | TradeWins (Ad)aTyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of EfzofitimodSeptember 2, 2026 | finance.yahoo.comaTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis StudySeptember 1, 2026 | quiverquant.comQaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary SarcoidosisSeptember 1, 2026 | globenewswire.comaTyr Pharma Inc 471AAugust 12, 2026 | morningstar.comMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (EMBC) and aTyr Pharma (ATYR)August 12, 2026 | theglobeandmail.comSee More Headlines ATYR Stock Analysis - Frequently Asked Questions How have ATYR shares performed this year? aTyr Pharma's stock was trading at $0.7831 at the start of the year. Since then, ATYR shares have decreased by 45.1% and is now trading at $0.4298. How were aTyr Pharma's earnings last quarter? aTyr Pharma, Inc. (NASDAQ:ATYR) issued its quarterly earnings data on Friday, August, 7th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The firm had revenue of $189.56 million for the quarter. When did aTyr Pharma IPO? aTyr Pharma (ATYR) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,360,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of aTyr Pharma? Shares of ATYR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of aTyr Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include ChargePoint (CHPT), Plug Power (PLUG), Chemomab Therapeutics (CMMB), Curaleaf (CURLF), Dare Bioscience (DARE), Jiuzi (JZXN) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings8/07/2026Today9/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ATYR's financial health is in the Red zone, according to TradeSmith. ATYR has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ATYR Previous SymbolNASDAQ:ATYR CIK1339970 Webatyrpharma.com Phone(858) 731-8389Fax858-731-8394Employees53Year Founded2005Profitability EPS (Trailing Twelve Months)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.12 million Net MarginsN/A Pretax Margin-32,006.32% Return on Equity-95.89% Return on Assets-69.67% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.12 Sales & Book Value Annual Sales$190 thousand Price / Sales221.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book0.62Miscellaneous Outstanding Shares98,090,000Free Float92,447,000Market Cap$42.16 million OptionableOptionable Beta0.53 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ATYR) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
